Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Hashim A, 2020
 
NCT04591600
RCTdoxycyclinestandard of careCOVID 19 hospitalizedsome concern
70/70 inconclusive
  • inconclusive 52 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

NCT04523831 (Mahmud), 2020
 
NCT04523831
RCTdoxycyclinestandard of careCOVID-19 mild to moderatehigh
200/200 safety concern
  • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
  • suggested 93 % increase in clinical improvement (7-day) (PE) but with a low degree of certainty due to high risk of bias
  • suggested 56 % decrease in clinical deterioration but with a low degree of certainty due to high risk of bias
  • statistically significant 17.6-fold increase in adverse events but with a low degree of certainty due to high risk of bias
results from clinicaltrial.gov
Spoorthi, 2020 NRadoxycyclineplaceboCOVID 19 hospitalized, COVID-19 mild to moderateNA
50/50 inconclusive

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).